 
      DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPITÂŽ, DBVâs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, we are dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVâs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. Source
No articles found.
 
                  Quanterix is a company that is digitizing biomarker analysis with the goal of adva...
Quanterix is a company that is digitizing bioma...
 
                  Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
 
                  Horizon is a biopharmaceutical company focused on researching, developing and comm...
Horizon is a biopharmaceutical company focused ...
 
                  CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
 
                  ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...
ANGLE is a world leading liquid biopsy company ...
 
                  Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
Join the National Investor Network and get the latest information with your interests in mind.